AACR年会是全球最具影响力的肿瘤领域学术盛会之一。2023 AACR将于4月14日-19日在美国奥兰多举行。医脉通特别整理了将要公布的相关最新进展,以飨读者。
口头报告专场:
CTMS02-Targeting the KRAS Pathway in the Clinic
April 17, 2023, 2:30 PM - 4:30 PM
摘要号:CT028
A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
关于LY3537982 的首次人体1期研究:一种高选择性KRAS G12C抑制剂用于晚期实体瘤患者的疗效
报告人:Yonina R. Murciano-Goroff
摘要号:CT029
Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation
GDC-6036联合西妥昔单抗治疗KRAS G12C突变结直肠癌患者的 Ib 期研究
报告人:Jayesh Desai
摘要号:CT030
Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: Updated results of the phase I study
IBI351 (GFH925) 单药治疗晚期实体瘤的 I 期研究更新结果
报告人:周清
摘要号:CT031
A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors
一项首次人体、1a/1b 期、开放标签、剂量递增和扩展研究:旨在评估RAF 二聚体抑制剂BGB-3245 在晚期或难治性肿瘤患者中的安全性、药代动力学和抗肿瘤活性
报告人:Alison M. Schram
摘要号:CT033
Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors
1b 期、开放标签、剂量递增和扩展研究:旨在评估RAF 二聚体抑制剂 lifirafenib +MEK抑制剂 mirdametinib用于晚期或难治性实体瘤的安全性、药代动力学和抗肿瘤活性
报告人:Benjamin Solomon
口头报告专场:
CTMS03-Novel Immunotherapy Combination Clinical Trials
April 18, 2023, 2:30 PM - 4:30 PM
摘要号:CT034
GLIMMER-01: initial results from a phase 1 dose escalation trial of a first-in-class bi-sialidase (E-602) in solid tumors
GLIMMER-01:首创双唾液酸酶(E-602)在实体瘤中的 1 期剂量递增试验初步结果
报告人:Jason J. Luke
摘要号:CT035
Addition of Salmonella-IL2 to FOLFIRINOX for metastatic stage 4 pancreatic cancer nearly doubles median survival
FOLFIRINOX方案联合Salmonella-IL2治疗转移性IV期胰腺癌使中位总生存期几乎翻倍
报告人:Daniel A. Saltzman
摘要号:CT036
Safety and immunogenicity of a first-in-human mutant KRAS long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer: Preliminary analysis from a phase I study
靶向mKRAS的长肽疫苗+伊匹木单抗/纳武利尤单抗用于可切除胰腺癌患者的安全性和免疫原性:首次人体I 期研究的初步分析
报告人:Saurav D. Haldar
摘要号:CT039
Immunomodulatory effects of ceralasertib in combination with durvalumab in patients with NSCLC and progression on anti-PD-(L)1 treatment (HUDSON, NCT03334617)
ceralasertib+度伐利尤单抗对PD-(L)1单抗治疗进展NSCLC患者的免疫调节作用(HUDSON)
报告人:Sonia Iyer
摘要号:CT040
A first-in-human phase 1 trial of IO-108, an antagonist antibody targeting LILRB2 (ILT4), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors: Dose escalation study
IO-108(一种靶向 LILRB的抑制性抗体)的首次人体1期剂量递增试验:单一疗法或联合帕博利珠单抗治疗晚期复发或难治性实体瘤的成年患者
报告人:Matthew H. Taylor
口头报告专场:
CTPL01 - Harnessing the Immune System in the Clinic
April 16, 2023, 12:45 PM - 3:15 PM
Session Type:Clinical Trials Plenary
摘要号:CT003
IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
IMbrave050:阿替利珠单抗+贝伐珠单抗辅助治疗vs主动监测治疗切除或消融后疾病复发高风险肝细胞癌 (HCC) 患者的3期研究
报告人:Pierce Chow
摘要号:CT004
Intratumoral (IT) MEDI1191 + durvalumab (D): Update on the first-in-human study in advanced solid tumors
瘤内 (IT) MEDI1191+度伐利尤单抗 (D)用于晚期实体瘤的首次人体研究最新结果
报告人:Eduardo Castañón
摘要号:CT005
AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC
AEGEAN:新辅助度伐利尤单抗+化疗、度伐利尤单抗辅助治疗用于可切除 NSCLC 患者的 3 期试验
报告人:John V. Heymach
口头报告专场:
CTPL02-Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents
April 16, 2023, 3:30 PM - 5:30 PM
Session Type:Clinical Trials Plenary Session
摘要号:CT006
First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations
首创新药VT3989(一种YAP/转录增强子激活域[TEAD]抑制剂)的首次人体1期试验:评估VT3989用于NF2突变恶性实体瘤尤其是恶性间皮瘤和其他肿瘤的结果
报告人:Timothy A. Yap
摘要号:CT007
Phase 2-3 trial of pegargiminase plus chemotherapy versus placebo plus chemotherapy in patients with non-epithelioid pleural mesothelioma
pegargiminase+化疗对比安慰剂+化疗用于非上皮样胸膜间皮瘤患者的 2-3 期试验
报告人:Peter W. Szlosarek
摘要号:CT008
Pembrolizumab (pembro) in combination with gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC): Phase 3 KEYNOTE-966 study
帕博利珠单抗+吉西他滨和顺铂 (gem/cis) 治疗晚期胆道癌 (BTC)的疗效:3 期 KEYNOTE-966 研究
报告人:Robin Kate Kelley
摘要号:CT009
S1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma
S1512:转移性促纤维增生性黑色素瘤患者接受PD-1单抗的高应答率
报告人:Kari Kendra
口头报告专场:
CTPL03-Promising Novel Antitumor Strategies in Early Phase Clinical Trials
April 17, 2023, 10:15 AM - 12:15 PM
Session Type:Clinical Trials Plenary Session
摘要号:CT011
A phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC)
一项评估 ALLO-316 用于经治晚期或转移性透明细胞肾细胞癌(ccRCC)患者安全性和有效性的 1 期多中心研究 (TRAVERSE)
报告人:Samer Srour
摘要号:CT012
Cinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC)
MCLA-158(petosemtamab,一种靶向EGFR/LGR5双特异性抗体)用于晚期头颈部鳞状细胞癌(HNSCC)患者的临床活性
报告人:Ezra E. W. Cohen
摘要号:CT014
Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer
分次剂量225Ac J591治疗转移性去势抵抗性前列腺癌的 I 期剂量递增研究
报告人:Jones T. Nauseef
口头报告专场:
CTPL04-Novel Biomarker-driven Molecularly Targeted Therapy Trials
April 18, 2023, 10:15 AM - 12:15 PM
Session Type:Clinical Trials Plenary Session
摘要号:CT017
Pan-mutant and isoform selective PI3Kα inhibitor, RLY-2608, demonstrates selective targeting in a first-in-human study of PIK3CA-mutant solid tumor patients, ReDiscover trial
泛PI3Kα抑制剂RLY-2608在PIK3CA突变体实体瘤患者中的首次人体研究:ReDiscover 试验
报告人:Andreas Varkaris
摘要号:CT018
Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations
三种PARP抑制剂(PARPi)+共济失调性毛细血管扩张和 Rad3 相关激酶抑制剂(ATRi)camonsertib用于DNA损伤反应(DDR)突变实体瘤患者的安全性和有效性
报告人:Timothy A. Yap
壁报专场:
PO.CT01.03 - Phase I Clinical Trials 1
April 18, 2023, 9:00 AM - 12:30 PM
摘要号:CT200 / 13
Updated PFS & OS from the phase Ib study of TQB2450 alone/with Anlotinib in previously treated advanced non-small cell lung cancer
TQB2450±安罗替尼治疗经治晚期非小细胞肺癌:Ib 期研究更新PFS和 OS结果
报告人:韩宝惠
摘要号:CT201 / 14
HS-10365, a highly potent and selective RET tyrosine kinase inhibitor, demonstrates robust activity in RET fusion positive NSCLC patients
HS-10365,一种高效、选择性RET酪氨酸激酶抑制剂,在RET融合阳性 NSCLC患者中显示出强大的抗肿瘤活性
报告人:陆舜
摘要号:CT204 / 17
Safety, tolerability, pharmacokinetics, and efficacy of SHR-A1811, an antibody-drug conjugate, in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC): a multicenter, open-label, phase 1/2 study
SHR-A1811(一种抗体偶联药物)在晚期HER2突变NSCLC患者中的安全性、耐受性、药代动力学和疗效:一项多中心、开放标签、1/2期研究
报告人:陆舜
摘要号:CT208 / 21
Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with untreated, unresectable, recurrent or metastatic, mucosal melanoma: An open-label, single-arm, Phase 1 study
Tebotelimab(一种 PD-1/LAG-3 双特异性抗体)用于初治、不可切除、复发或转移的黏膜黑色素瘤患者的疗效:一项开放标签、单臂、1 期研究
报告人:斯璐
壁报专场:
PO.CT03.01-Phase III and Pediatric Clinical Trials
April 17, 2023, 9:00 AM - 12:30 PM
摘要号:CT075 / 3
Updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-15)
信迪利单抗+化疗对比安慰剂+化疗用于晚期食管鳞癌一线治疗的随机、双盲 III 期研究更新总生存期结果(ORIENT-15)
报告人:鲁智豪
摘要号:CT076 / 4
Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis
替雷利珠单抗联合化疗对比化疗用于晚期或转移性食管鳞癌一线治疗的随机、全球、3期研究(RATIONALE-306):中国亚组分析
报告人:束永前
摘要号:CT079 / 7
Efficacy and safety of sintilimab (anti-PD-1 mAb) for advanced cervical cancer: Results from a Phase II trial
信迪利单抗(PD-1单抗)治疗晚期宫颈癌的疗效和安全性:II 期试验结果
报告人:高庆蕾
摘要号:CT081 / 9
Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in Chinese patients (pts) with resectable NSCLC in CheckMate 816
新辅助纳武利尤单抗+化疗对比化疗用于可切除NSCLC患者更新分析:CheckMate 816
报告人:王长利
摘要号:CT063 / 21
A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)
既往CDK4/6 抑制剂+非甾体芳香化酶抑制剂治疗进展HR+/HER2- 晚期乳腺癌患者使用 gedatolisib+氟维司群±哌柏西利的3 期研究:VIKTORIA-1研究
报告人:Sara A. Hurvitz
摘要号:CT064 / 22
Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01
评估 GLSI-100(GP2 + GM-CSF)新辅助和术后HER2辅助治疗用于残留疾病或高风险 PCR乳腺癌患者的有效性和安全性:III 期研究Flamingo -01研究
报告人:Snehal S. Patel
摘要号:CT065 / 23
Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)
tucatinib 或安慰剂+曲妥珠单抗+帕妥珠单抗用于HER2+转移性乳腺癌维持治疗的3期研究:3期HER2CLIMB-05
报告人:Ciara C. O’Sullivan
摘要号:CT066 / 24
HERTHENA-Lung02: A randomized Phase 3 study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR tyrosine kinase inhibitor
HERTHENA-Lung02:patritumab deruxtecan对比铂类化疗用于第三代 EGFR TKI进展后局部晚期或转移性EGFR突变NSCLC患者的随机3期研究
报告人:Balazs Halmos
摘要号:CT067 / 25
Pembrolizumab with and without sacituzumab govitecan as first-line treatment for metastatic non-small-cell lung cancer (NSCLC) with PD-L1 TPS ≥50%: phase 3 KEYNOTE-D46/EVOKE-03 study
帕博利珠单抗±sacituzumab govitecan用于PD-L1 TPS ≥ 50%转移性NSCLC患者的一线治疗:3 期 KEYNOTE-D46/EVOKE-03 研究
报告人:Mor Moskovitz
壁报专场:
PO.CT01.01 - First-in-Human Phase I Clinical Trials 1
April 17, 2023, 1:30 PM - 5:00 PM
摘要号:CT102 / 10
Interim results of a first-in-human, dose escalation and expansion study of PLB-1004, an irreversible inhibitor of exon 20 insertion mutations in patients with non-small cell lung cancer
PLB-1004(一种外显子20插入突变不可逆抑制剂)用于NSCLC的首次人体剂量递增和扩展研究中期结果
报告人:杨衿记
摘要号:CT097 / 5
First report of preliminary safety, efficacy, and pharmacokinetics of C-CAR031 (GPC3-specific TGFβRIIDN CAR-T) in patients with advanced HCC
C-CAR031(GPC3特异性TGFβRIIDN CAR-T)用于晚期HCC患者的初步安全性、有效性和药代动力学初步结果
报告人:Qi Zhang
摘要号:CT099 / 7
First-in-human study of ALF501, polypeptide PSMA-targeted chimeric antigen receptor engineered natural killer cells) for castration-resistant prostate cancer
ALF501首次人体研究:靶向PSMA CAR-T疗法用于前列腺癌患者的疗效。
报告人:Hui Shi
壁报专场:
PO.CT01.02 - First-in-Human Phase I Clinical Trials 2
April 18, 2023, 9:00 AM - 12:30 PM
摘要号:CT175 / 7
Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing/mutated advanced solid tumors: A global phase 1, multi-center, first-in-human study
SHR-A1811在HER2 表达/突变晚期实体瘤中的安全性、耐受性、药代动力学和抗肿瘤活性:全球 1 期、多中心、首次人体研究
报告人:姚和瑞
摘要号:CT181 / 13
A first-in-human (FIH) phase 1 study of SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors
I期试验:SHR-A1921(一种靶向 TROP-2 ADC)在晚期实体瘤患者中的首次人体1 期研究
报告人:王洁
壁报专场:
PO.CT02.01 - Phase II Clinical Trials 1
April 17,2023,1:30 PM - 5:00 PM
摘要号:CT150 / 12
Result of an open-label phase 2 trial of dual TORC1/TORC2 inhibitor onatasertib (ATG-008) in HBV+ advanced hepatocellular carcinoma (HCC) subjects who have received at least one prior line of systemic therapy (TORCH)
TORC1/TORC2 双抑制剂 onatasertib(ATG-008)在既往至少接受过一次全身治疗HBV+ 晚期HCC患者中的一项开放标签 2 期试验结果:TORCH研究
报告人:秦叔逵
摘要号:CT152 / 14
A multicenter Phase II study of savolitinib in patients with MET-amplified gastroesophogeal junction adenocarcinomas or gastric cancer
赛沃替尼在MET扩增胃食管交界处腺癌或胃癌患者中的多中心 II 期研究
报告人:沈琳
壁报专场:
PO.CT02.02 - Phase II Clinical Trials 2
April 18,2023,9:00 AM - 12:30 PM
摘要号:CT225 / 15
Surufatinib plus toripalimab for first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 positive expression: A multicenter, single-arm phase 2 study
索凡替尼联合特瑞普利单抗一线治疗 PD-L1 阳性晚期NSCLC患者的研究:一项多中心、单组 2 期研究
报告人:程颖